Artivion, Inc. filings document the regulatory record for a medical device company focused on aortic disease and related tissue preservation services. Recent Form 8-K disclosures furnish quarterly and annual operating results, clinical and regulatory updates, material agreements, and capital-structure matters, including credit-facility amendments and secured delayed draw term loan financing.
Proxy materials describe annual meeting voting, board governance, executive compensation, and shareholder matters. Other current reports document leadership appointments, material contracts, facilities-related agreements tied to the company’s operations, and disclosures connected to products such as aortic stent grafts, On-X mechanical heart valves, surgical sealants, and implantable cardiac and vascular human tissues.
Artivion, Inc. has completed its acquisition of Endospan Ltd., an Israeli company focused on endovascular treatment of aortic arch disease and developer of the NEXUS Aortic Arch System. The deal includes a base purchase price of $175.0 million, paid entirely in cash and subject to customary adjustments.
Securityholders of Endospan may receive up to an additional $200.0 million in contingent consideration based on future performance of the NEXUS product, determined about two years after closing. Artivion used a previously drawn $150 million delayed draw term loan to fund a $135 million upfront net purchase price and placed $17.5 million into escrow for indemnity and adjustment purposes.
The U.S. Food and Drug Administration approved the premarket approval application for the NEXUS branched endovascular stent graft system in April 2026. Artivion, already the exclusive NEXUS distributor across EMEA since 2019, says the acquisition completes its three-pronged aortic arch portfolio alongside AMDS and ARCEVO LSA and adds a pipeline of next-generation arch technologies.
Artivion, Inc. reported results from its 2026 Annual Meeting of Stockholders held on May 12, 2026. Stockholders elected all nine nominated directors, with support levels generally above 34 million votes for each nominee and broker non-votes of 5,607,747 on each director item.
Stockholders also approved, by a non-binding advisory vote, the compensation of Artivion’s named executive officers, with 36,876,134 votes for, 2,291,059 against and 151,868 abstentions, alongside 5,607,747 broker non-votes. In addition, stockholders ratified the preliminary selection of Ernst & Young LLP as Artivion’s independent registered public accounting firm for the year ending December 31, 2026, with 44,294,062 votes for, 625,438 against and 7,308 abstentions.
Artivion, Inc. reported strong quarterly growth, with revenues for the three months ended March 31, 2026 rising 18% to $116.3 million and net income improving to $1.4 million from a prior-year loss. Growth was driven by higher sales of aortic stent grafts, On‑X heart valves, surgical sealants, and preservation services, plus favorable foreign exchange.
Gross margin increased to $75.4 million, or 65% of revenue, helped by a richer product mix and higher pricing. Operating income more than doubled to $5.8 million as revenue growth outpaced higher spending on sales, marketing, and research and development.
Artivion ended the quarter with $55.8 million in cash and $220.0 million of principal debt outstanding, and generated positive operating cash flow of $1.2 million. The company exercised its option to acquire Endospan, planning to fund the $135.0 million upfront purchase price with a $150.0 million delayed draw term loan facility.
Artivion reported a strong first quarter and moved to acquire its longtime partner Endospan. Revenue for Q1 2026 rose to $116.3 million from $99.0 million, up 18% on a GAAP basis and 12% on a constant currency basis. Net income was $1.4 million, or $0.03 per diluted share, compared with a small loss a year earlier, while non-GAAP net income increased to $4.2 million, or $0.08 per diluted share. Adjusted EBITDA grew 26% to $22.1 million, driven by double‑digit gains in aortic stent grafts, On‑X valves, and preservation services.
The company exercised its option to acquire Endospan after FDA PMA approval of the NEXUS Aortic Arch System. The base purchase price is $175.0 million, with an expected net upfront payment of about $135.0 million after loan offsets, plus up to $200.0 million of contingent consideration based on future product performance. Artivion plans to fund the deal with borrowings under its term loan facility and expects closing in the second quarter, subject to customary conditions.
Management lowered full‑year 2026 guidance despite the strong start. Revenue is now expected between $480 million and $496 million, implying 7% to 11% adjusted constant currency growth, and adjusted EBITDA is forecast at $100 million to $107 million, or 12% to 20% growth, both reduced from prior targets.
Artivion, Inc. is asking stockholders to vote at its virtual-only 2026 Annual Meeting on May 12, 2026 at 9:00 a.m. ET. Holders of common stock as of March 16, 2026 may vote on electing nine directors, approving executive pay on an advisory basis, and ratifying Ernst & Young LLP as independent auditor for 2026.
The Board states all non-employee directors are independent under NYSE rules and recommends voting FOR all director nominees, FOR the advisory “Say on Pay” resolution, and FOR auditor ratification. The proxy also describes virtual participation, quorum and voting standards, director compensation, board committee structure, and Artivion’s corporate governance and sustainability practices.
Artivion Inc received Amendment No. 6 to a Schedule 13G/A from The Vanguard Group that reports zero shares beneficially owned of Common Stock and 0% of the class. The filing reflects an internal realignment on January 12, 2026 under SEC Release No. 34-39538, after which certain Vanguard subsidiaries will report holdings separately. The filing lists Vanguard's Malvern, PA address and states that no single other person holds more than 5% of the class. The form is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
ARTIVION, INC. VP and Chief Accounting Officer Amy Horton reported both a stock award and a small share sale. She received 7,475 shares of common stock on March 2, 2026 as part of a performance stock unit grant made on February 28, 2025, with additional portions scheduled to vest in 2027 and 2028 if she remains employed on those dates. On March 3, 2026, 901 shares were sold at an average price of $37.7756 to cover tax withholding obligations arising from the vesting of performance stock units, and this "sell to cover" was described as non-discretionary. After the sale, she directly held 139,088 shares of common stock.
ARTIVION, INC. executive Jean F. Holloway, SVP and General Counsel, reported equity compensation activity and related tax sales in company stock. She acquired 27,795 shares of common stock on a grant or award basis at $0.00 per share, tied to performance stock units granted in February 2025, with remaining portions scheduled to vest in February 2027 and February 2028 subject to continued employment. Following this vesting, she sold 3,843 shares at an average price of $37.7756 on March 3, 2026 and 8,962 shares at $38.00 on March 4, 2026 solely to cover tax withholding obligations under a “sell to cover” arrangement, which the filing states is not a discretionary transaction. After these transactions, she directly owned 185,095 shares of Artivion common stock.
ARTIVION, INC. senior vice president Stanton Marshall S. reported two stock transactions involving company common shares. He acquired 21,838 shares on a grant/award basis at $0.0000 per share as part of performance stock units granted in February 2025. According to the award terms, additional portions of this grant are eligible to vest on February 28, 2027 and February 28, 2028, subject to continued employment on each vesting date. On March 3, 2026, 2,149 shares were sold at an average price of $37.7756 per share to cover tax withholding obligations through a sell-to-cover transaction, which the company notes was not a discretionary sale. After these transactions, Marshall directly owned 60,097 shares of Artivion common stock.